Cirena Licenses Agilent RNA Purification Technology to Scale High-Purity Long RNA for Genome Editing

Upstream purity failures in long RNA manufacturing have constrained genome editing programs for years, Cirena's licensing agreement with Agilent Technologies signals a direct attempt to close that gap at commercial scale. The deal grants Cirena access to Agilent's RNA purification platform, targeting the chemical purity challenges that emerge as RNA constructs extend beyond 100 nucleotides.

For CMOs and biotech manufacturers building out RNA drug substance suites, the technical context is consequential. Long RNA molecules accumulate truncated sequences, double-stranded RNA impurities, and residual synthesis byproducts at a rate that shorter constructs do not. Conventional downstream processing, including standard HPLC and precipitation methods, loses resolution at these chain lengths, creating a process validation liability that sits squarely within ICH Q10 quality system expectations and 21 CFR Part 211 in-process control requirements.

Agilent's purification technology is designed to maintain separation performance across extended RNA lengths, which directly affects the sterility assurance and potency consistency profiles that regulatory submissions depend on. For QA directors managing release specifications on RNA-based therapeutics, the ability to demonstrate reproducible purity at scale is a prerequisite for any comparability exercise across manufacturing sites or process changes.

Cirena's focus on genome editing adds a further layer of regulatory scrutiny. Guide RNAs and large messenger RNA constructs used in CRISPR-based modalities require purity thresholds that support both preclinical safety packages and eventual IND filings; impurity carryover at this stage has downstream consequences for clinical hold risk. Licensing an established analytical and purification platform, rather than developing in-house capability, compresses the process development timeline and provides a documented technology provenance that regulators can interrogate.

The agreement positions Cirena to offer high-purity long RNA as a defined manufacturing output, which carries direct implications for any CDMOs evaluating platform partnerships ahead of capacity build-outs in the RNA therapeutics space.

The extent to which this platform supports GMP-scale batch consistency will become measurable once Cirena advances programs through formal process validation campaigns.

Source: Media4Growth via Indian Pharma Post, 7 May 2026.